Loading patent
US12594332B2 · 04/07/2026
What is claimed is: 1 . A method of treating psoriasis, comprising administering to a patient in need thereof about 150 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter. 2 . The method of claim 1 , wherein the patient has plaque psoriasis. 3 .
Abstract The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
No articles yet — metadata is still available from the registry.
0 replies · cite patents with ^
Join the discussion
Continue with GoogleNo comments yet.
